Among patients with chondrosarcomas, the most common primary bone tumor in adults, the presence of a TP53 gene mutation has been found to be associated with worse overall survival and metastasis-free ...

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...

Longer intervals between the diagnosis of MPN or MPN/MDS and TP53 detection are associated with a worse prognosis.

Patients with myelofibrosis (MF) with single-hit mutations had similar outcomes to patients with wild-type TP53. People with myelofibrosis (MF) who undergo hematopoietic stem cell transplantation ...

Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study. This is an ASCO Meeting ...

Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98 We assessed TP53 mutations by denaturing high-performance ...

Lung cancer is the most common and deadly form of cancer worldwide. It is increasingly understood to be a complex genetic disease with different mutations that vary according to factors such as ...

The transcription factor TP53 exhibits the preeminent frequency of genetic mutations across various cancer types. Long non-coding RNAs (lncRNAs) stand as pivotal molecules in the initiation and ...

The ERK1/2 signaling pathway, one of the most frequently dysregulated oncogenic pathways, can be initiated by diverse mutations, including those in RAS, BRAF, and amplifications of ERBB2 (HER2).

In a recent study published in Nature Genetics, researchers performed an allelic-level single-cellular multi-omics evaluation of hematopoietic stem/progenitor cells (HSPCs) obtained from individuals ...